Hairy cell leukemia: Evaluation of the long-term outcome in 121 patients

Pier Luigi Zinzani, Cinzia Pellegrini, Vittorio Stefoni, Enrico Derenzini, Letizia Gandolfi, Alessandro Broccoli, Lisa Argnani, Federica Quirini, Stefano Pileri, Michele Baccarani

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

BACKGROUND: Historically, the first treatment choices for hairy cell leukemia (HCL) were splenectomy and alphainterferon. Recently, purine analogues (pentostatin and cladribine) changed radically the treatment modality, inducing complete and durable responses in the majority of patients. METHODS: The authors analyzed the outcome of different lines of therapy in 121 HCL patients followed in their institute from 1986 to 2008, with a median follow-up of 105 months. Patients were divided into subgroups according to the number of treatments; Group A included 121 patients who underwent a front-line therapy, Group B patients (n = 53) were treated with 2 lines, Group C patients (n = 34) with 3 lines, Group D patients (n = 17) with 4 lines, and Group E patients (n = 8) with 5 lines. RESULTS: In Group A, 92 (77%) patients obtained a complete response (CR), 23 (18%) a partial response, and the remaining 6 (5%) a minor or no response; median duration of response was 2.7 years. In Group B, 53 relapsed patients achieved a second CR rate of 73.5%; median duration of response was 2.5 years. Group C contained 34 patients in a second relapse, with a CR rate after the third line of treatment of 70.5% (median duration of response, 2.2 years). In Group D, 11 (64.7%) patients obtained a CR (median duration of response, 1.6 years), and in Group E 4 (50%) of 8 patients achieved a CR (median duration of response, 1.3 years). CONCLUSIONS: This study confirms the high risk (>40% of all patients) of retreatment of HCL patients and the need to maximize primary response.

Original languageEnglish
Pages (from-to)4788-4792
Number of pages5
JournalCancer
Volume116
Issue number20
DOIs
Publication statusPublished - 2010

Fingerprint

Hairy Cell Leukemia
Pentostatin
Cladribine
Therapeutics
Retreatment
Splenectomy
Group Psychotherapy

Keywords

  • Alpha-interferon
  • Cladribine
  • Hairy cell leukemia
  • Pentostatin
  • Rituximab
  • Splenectomy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Zinzani, P. L., Pellegrini, C., Stefoni, V., Derenzini, E., Gandolfi, L., Broccoli, A., ... Baccarani, M. (2010). Hairy cell leukemia: Evaluation of the long-term outcome in 121 patients. Cancer, 116(20), 4788-4792. https://doi.org/10.1002/cncr.25243

Hairy cell leukemia : Evaluation of the long-term outcome in 121 patients. / Zinzani, Pier Luigi; Pellegrini, Cinzia; Stefoni, Vittorio; Derenzini, Enrico; Gandolfi, Letizia; Broccoli, Alessandro; Argnani, Lisa; Quirini, Federica; Pileri, Stefano; Baccarani, Michele.

In: Cancer, Vol. 116, No. 20, 2010, p. 4788-4792.

Research output: Contribution to journalArticle

Zinzani, PL, Pellegrini, C, Stefoni, V, Derenzini, E, Gandolfi, L, Broccoli, A, Argnani, L, Quirini, F, Pileri, S & Baccarani, M 2010, 'Hairy cell leukemia: Evaluation of the long-term outcome in 121 patients', Cancer, vol. 116, no. 20, pp. 4788-4792. https://doi.org/10.1002/cncr.25243
Zinzani PL, Pellegrini C, Stefoni V, Derenzini E, Gandolfi L, Broccoli A et al. Hairy cell leukemia: Evaluation of the long-term outcome in 121 patients. Cancer. 2010;116(20):4788-4792. https://doi.org/10.1002/cncr.25243
Zinzani, Pier Luigi ; Pellegrini, Cinzia ; Stefoni, Vittorio ; Derenzini, Enrico ; Gandolfi, Letizia ; Broccoli, Alessandro ; Argnani, Lisa ; Quirini, Federica ; Pileri, Stefano ; Baccarani, Michele. / Hairy cell leukemia : Evaluation of the long-term outcome in 121 patients. In: Cancer. 2010 ; Vol. 116, No. 20. pp. 4788-4792.
@article{da7b3e78382847c18df4bd33e07d5412,
title = "Hairy cell leukemia: Evaluation of the long-term outcome in 121 patients",
abstract = "BACKGROUND: Historically, the first treatment choices for hairy cell leukemia (HCL) were splenectomy and alphainterferon. Recently, purine analogues (pentostatin and cladribine) changed radically the treatment modality, inducing complete and durable responses in the majority of patients. METHODS: The authors analyzed the outcome of different lines of therapy in 121 HCL patients followed in their institute from 1986 to 2008, with a median follow-up of 105 months. Patients were divided into subgroups according to the number of treatments; Group A included 121 patients who underwent a front-line therapy, Group B patients (n = 53) were treated with 2 lines, Group C patients (n = 34) with 3 lines, Group D patients (n = 17) with 4 lines, and Group E patients (n = 8) with 5 lines. RESULTS: In Group A, 92 (77{\%}) patients obtained a complete response (CR), 23 (18{\%}) a partial response, and the remaining 6 (5{\%}) a minor or no response; median duration of response was 2.7 years. In Group B, 53 relapsed patients achieved a second CR rate of 73.5{\%}; median duration of response was 2.5 years. Group C contained 34 patients in a second relapse, with a CR rate after the third line of treatment of 70.5{\%} (median duration of response, 2.2 years). In Group D, 11 (64.7{\%}) patients obtained a CR (median duration of response, 1.6 years), and in Group E 4 (50{\%}) of 8 patients achieved a CR (median duration of response, 1.3 years). CONCLUSIONS: This study confirms the high risk (>40{\%} of all patients) of retreatment of HCL patients and the need to maximize primary response.",
keywords = "Alpha-interferon, Cladribine, Hairy cell leukemia, Pentostatin, Rituximab, Splenectomy",
author = "Zinzani, {Pier Luigi} and Cinzia Pellegrini and Vittorio Stefoni and Enrico Derenzini and Letizia Gandolfi and Alessandro Broccoli and Lisa Argnani and Federica Quirini and Stefano Pileri and Michele Baccarani",
year = "2010",
doi = "10.1002/cncr.25243",
language = "English",
volume = "116",
pages = "4788--4792",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "20",

}

TY - JOUR

T1 - Hairy cell leukemia

T2 - Evaluation of the long-term outcome in 121 patients

AU - Zinzani, Pier Luigi

AU - Pellegrini, Cinzia

AU - Stefoni, Vittorio

AU - Derenzini, Enrico

AU - Gandolfi, Letizia

AU - Broccoli, Alessandro

AU - Argnani, Lisa

AU - Quirini, Federica

AU - Pileri, Stefano

AU - Baccarani, Michele

PY - 2010

Y1 - 2010

N2 - BACKGROUND: Historically, the first treatment choices for hairy cell leukemia (HCL) were splenectomy and alphainterferon. Recently, purine analogues (pentostatin and cladribine) changed radically the treatment modality, inducing complete and durable responses in the majority of patients. METHODS: The authors analyzed the outcome of different lines of therapy in 121 HCL patients followed in their institute from 1986 to 2008, with a median follow-up of 105 months. Patients were divided into subgroups according to the number of treatments; Group A included 121 patients who underwent a front-line therapy, Group B patients (n = 53) were treated with 2 lines, Group C patients (n = 34) with 3 lines, Group D patients (n = 17) with 4 lines, and Group E patients (n = 8) with 5 lines. RESULTS: In Group A, 92 (77%) patients obtained a complete response (CR), 23 (18%) a partial response, and the remaining 6 (5%) a minor or no response; median duration of response was 2.7 years. In Group B, 53 relapsed patients achieved a second CR rate of 73.5%; median duration of response was 2.5 years. Group C contained 34 patients in a second relapse, with a CR rate after the third line of treatment of 70.5% (median duration of response, 2.2 years). In Group D, 11 (64.7%) patients obtained a CR (median duration of response, 1.6 years), and in Group E 4 (50%) of 8 patients achieved a CR (median duration of response, 1.3 years). CONCLUSIONS: This study confirms the high risk (>40% of all patients) of retreatment of HCL patients and the need to maximize primary response.

AB - BACKGROUND: Historically, the first treatment choices for hairy cell leukemia (HCL) were splenectomy and alphainterferon. Recently, purine analogues (pentostatin and cladribine) changed radically the treatment modality, inducing complete and durable responses in the majority of patients. METHODS: The authors analyzed the outcome of different lines of therapy in 121 HCL patients followed in their institute from 1986 to 2008, with a median follow-up of 105 months. Patients were divided into subgroups according to the number of treatments; Group A included 121 patients who underwent a front-line therapy, Group B patients (n = 53) were treated with 2 lines, Group C patients (n = 34) with 3 lines, Group D patients (n = 17) with 4 lines, and Group E patients (n = 8) with 5 lines. RESULTS: In Group A, 92 (77%) patients obtained a complete response (CR), 23 (18%) a partial response, and the remaining 6 (5%) a minor or no response; median duration of response was 2.7 years. In Group B, 53 relapsed patients achieved a second CR rate of 73.5%; median duration of response was 2.5 years. Group C contained 34 patients in a second relapse, with a CR rate after the third line of treatment of 70.5% (median duration of response, 2.2 years). In Group D, 11 (64.7%) patients obtained a CR (median duration of response, 1.6 years), and in Group E 4 (50%) of 8 patients achieved a CR (median duration of response, 1.3 years). CONCLUSIONS: This study confirms the high risk (>40% of all patients) of retreatment of HCL patients and the need to maximize primary response.

KW - Alpha-interferon

KW - Cladribine

KW - Hairy cell leukemia

KW - Pentostatin

KW - Rituximab

KW - Splenectomy

UR - http://www.scopus.com/inward/record.url?scp=78349281132&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78349281132&partnerID=8YFLogxK

U2 - 10.1002/cncr.25243

DO - 10.1002/cncr.25243

M3 - Article

C2 - 20597132

AN - SCOPUS:78349281132

VL - 116

SP - 4788

EP - 4792

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 20

ER -